Treace Medical Concepts, Inc.

NASDAQ:TMCI

Medical - Devices

Healthcare
$4.53 +1.87%

+$0.08 today

Market cap
$296.98M
Beta
1.41
P/E (TTM)
-4.3
EPS (TTM)
-$0.95
52W Low $1.17High $7.78

Volume 0.18M

Average 0.73M

TMCI Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Treace Medical Concepts, Inc.NASDAQ: TMCI

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue dips below year-ago levels

Q1 FY2026 cost of revenue of $9.79M fell 8.3% year over year, behind the +1.0% change in trailing-twelve-month cost of revenue. Sequentially, it fell 19.2% from the prior quarter. Over 3 fiscal years it compounded at +16.0% a year.

Context

  • Cost of revenue amounted to 20.2% of revenue in FY2025, up 0.6 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -8.3% toward the trailing-twelve-month pace of +1.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.79M-19.2% QoQ
Last fiscal yearDec 2025
$42.94M+4.5% YoY
LTMMar 2026
$42.05M+1.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.3%——
1 year+4.5%——
3-year CAGR+16.0%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
42.94M USD
Year-over-year change
+4.5%
4-year CAGR
+26.3%

Cost of Revenue vs competitors

How TMCI compares with its peers on the latest reported figures

  • TMCI's LTM Mar 2026 cost of revenue of $42.05M is the 6th highest of the 8 companies compared; the peer median is $65.51M.
  • Its year-over-year change of +1.0% is the 5th highest of 8, against a peer median of +13.4%.
  • Cost of revenue amounts to 20.3% of revenue for TMCI, versus a peer median of 32.2%.
TMCI Competitors Peer median
Cost of Revenue for TMCI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TOIThe Oncology Institute, Inc.LTM Mar 2026$464.88M +35.2%+28.6%85.2%
BVSBioventus Inc.LTM Mar 2026$185.67M -0.4%+0.8%32.2%
EOLSEvolus, Inc.LTM Mar 2026$103.98M +17.4%+21.1%34.5%
KIDSOrthoPediatrics Corp.LTM Mar 2026$65.51M +13.4%+26.3%26.9%
LABStandard BioTools Inc.LTM Mar 2026$44.6M -34.2%-11.1%51.7%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$42.05M +1.0%+16.0%20.3%
RXSTRxSight, Inc.LTM Mar 2026$29.3M -43.5%+4.4%23.0%
CBLLCeriBell, Inc.LTM Mar 2026$11.68M +28.7%+34.5%12.3%
Peer median (excluding TMCI) $65.51M+13.4%+21.1%32.2%

Competitors are the stored peer set for TMCI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue94.42M141.84M187.12M209.36M212.69M
Cost of Revenue16.89M27.52M35.18M41.09M42.94M
Gross Profit77.53M114.32M151.94M168.26M169.75M
Gross Margin82.1%80.6%81.2%80.4%79.8%
Research & Development10.2M13.58M15.44M20.59M20.28M
Selling, General & Admin83.84M137.57M187.93M203.36M203.62M
Operating Expenses94.04M149.16M203.37M223.95M223.91M
Depreciation & Amortization685K2.13M5.35M8.42M10.5M
EBITDA(15.81M)(36.28M)(39.01M)(42.07M)(43.18M)
EBITDA Margin-16.7%-25.6%-20.8%-20.1%-20.3%
Operating Income(16.51M)(34.84M)(51.43M)(55.69M)(54.15M)
Operating Margin-17.5%-24.6%-27.5%-26.6%-25.5%
Interest Income18K1.31M6.73M4.88M2.78M
Interest Expense4.06M4.4M5.17M5.26M5.32M
Other Income / Expenses(4.04M)(7.97M)1.9M(55K)(4.85M)
Income Before Tax(20.55M)(42.82M)(49.53M)(55.74M)(59M)
Pre-Tax Margin-21.8%-30.2%-26.5%-26.6%-27.7%
Income Tax Expense00000
Net Income(20.55M)(42.82M)(49.53M)(55.74M)(59M)
Net Margin-21.8%-30.2%-26.5%-26.6%-27.7%
EPS (Basic)(0.38)(0.77)(0.81)(0.90)(0.93)
EPS (Diluted)(0.38)(0.77)(0.81)(0.90)(0.93)
Weighted Avg Shares54.18M55.28M60.85M62.11M63.27M
Weighted Avg Shares (Diluted)54.18M55.28M60.85M62.11M63.27M

Treace Medical Concepts, Inc.

NASDAQ:TMCI

Intrinsic Alpha fair value

Locked

Current Price

$4.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.